Liu Xun, Han Xuebing, Wei Shuqing, Zhang Changwen
Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Department of Urology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.
Front Oncol. 2024 Nov 1;14:1424677. doi: 10.3389/fonc.2024.1424677. eCollection 2024.
Tumor organoids, an three-dimensional model, possess high potential for investigating tumor biology and treatment response and have been demonstrated more appropriate for drug assessment than two-dimensional cultures. Herein, we described two cases of invasive high-grade urothelial carcinoma who underwent radical cystectomy successfully following use of patient-derived organoids (PDOs) for drug screening to inform therapeutic decisions. In these two cases, the PDOs cultured by biopsy tissues were both sensitive to the combination of gemcitabine and cisplatin. After neoadjuvant chemotherapy (NAC) with gemcitabine and cisplatin, the patients responded well, and radical cystectomy was performed successfully. No recurrence or metastasis was observed within 6 months after surgery. This small case series suggests that the patient-derived urothelial carcinoma organoids contribute to optimizing NAC options to guide personalized treatment and improve the survival outcomes.
肿瘤类器官作为一种三维模型，在研究肿瘤生物学和治疗反应方面具有很高的潜力，并且已被证明比二维培养更适合进行药物评估。在此，我们描述了两例浸润性高级别尿路上皮癌患者，在使用患者来源的类器官（PDO）进行药物筛选以指导治疗决策后，成功接受了根治性膀胱切除术。在这两例病例中，通过活检组织培养的PDO对吉西他滨和顺铂联合用药均敏感。在接受吉西他滨和顺铂新辅助化疗（NAC）后，患者反应良好，并成功进行了根治性膀胱切除术。术后6个月内未观察到复发或转移。这个小病例系列表明，患者来源的尿路上皮癌类器官有助于优化NAC方案，以指导个性化治疗并改善生存结果。
